Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial
Pamela S. Douglas(Duke University), Steven Grinspoon(Massachusetts General Hospital), Heather J. Ribaudo(Cancer Research And Biostatistics), Carl J. Fichtenbaum(Cancer Research And Biostatistics), Edgar T. Overton(University of Alabama at Birmingham), María Saumoy(Bellvitge University Hospital), Craig A. Sponseller, Udo Hoffmann(Duke Medical Center), Anchalee Avihingsanon(Chulalongkorn University), Flavio Bustorff(Universidade Iguaçu), Ann Marie Návar(The University of Texas Southwestern Medical Center), Kiat Ruxrungtham(Chulalongkorn University), Kathleen Melbourne(Gilead Sciences (United States)), Triin Umbleja(Harvard University), Gerald S. Bloomfield, Emma M. Kileel(Boston University), Judith S. Currier(University of California, Los Angeles), Kathleen V. Fitch(Harvard University), Markella V. Zanni(Harvard University), Judith A. Aberg(Icahn School of Medicine at Mount Sinai), Vicente Estrada(Instituto de Salud Carlos III)
Cited by 41
Related Papers
Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery
|New England Journal of Medicine|2010|7.2k
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
|New England Journal of Medicine|2011|7k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: Executive Summary
|Circulation|2012|2.4k
Two-Year Outcomes after Transcatheter or Surgical Aortic-Valve Replacement
|New England Journal of Medicine|2012|2.3k